Generate Biomedicines director awarded stock options

Vessey Rupert reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Vessey Rupert reported acquisition or exercise transactions in this Form 4 filing.

Generate Biomedicines director Rupert Vessey was granted a new stock option award. The Form 4 reports an option over 29,561 shares of Generate Biomedicines, Inc. common stock, held directly. Following this grant, he holds 29,561 derivative securities.

The footnote states that all shares underlying this option will vest in full on February 19, 2027, provided he continues to serve through that vesting date. This is an equity compensation grant rather than an open-market share purchase or sale.

Insider Trade Summary

Grant/Award: 29,561 shares

Grant/Award 1 txn

Insider Vessey Rupert

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	29,561	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 29,561 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GENB disclose for Rupert Vessey?

Generate Biomedicines (GENB) disclosed that director Rupert Vessey received a grant of stock options covering 29,561 shares. This was an equity award, not an open-market trade, and increases his derivative holdings to 29,561 options in the company.

Is the recent GENB Form 4 a buy or sell of shares?

The GENB Form 4 does not show a buy or sell in the market; it reports an option grant. Director Rupert Vessey acquired 29,561 stock options as a grant, classified as an award, rather than purchasing or disposing of existing shares.

When do Rupert Vessey’s GENB stock options vest?

According to the filing footnote, the stock options granted to Rupert Vessey vest in full on February 19, 2027. Vesting is conditional on his continued service with Generate Biomedicines through that date, aligning the award with long-term commitment.

How many GENB derivative securities does Rupert Vessey hold after this grant?

After the reported transaction, Rupert Vessey holds 29,561 derivative securities in GENB. These represent stock options from the latest equity award, all held as direct ownership, with vesting scheduled in 2027 subject to ongoing service.

Does the GENB Form 4 indicate any indirect ownership or special entities?

The GENB Form 4 classifies Rupert Vessey’s ownership of the granted options as direct, without mention of trusts, LLCs, or other entities. The footnote focuses solely on vesting terms tied to his continued service, not on alternative ownership structures.

What conditions are attached to the new GENB option grant?

The option grant to Rupert Vessey is subject to a service-based vesting condition. All 29,561 underlying shares will vest on February 19, 2027, only if he remains in service with Generate Biomedicines on that vesting date, as stated in the footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 06:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vessey Rupert

(Last) (First) (Middle)

GENERATE BIOMEDICINES, INC.

101 SOUTH STREET, SUITE 900

(Street)

SOMERVILLE MA 02143

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Generate Biomedicines, Inc. [ GENB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16	02/26/2026		A		29,561		(1)	02/25/2036	Common Stock	29,561	$0	29,561	D

Explanation of Responses:

1. The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

	/s/ Michael Wolf, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.